Overview

This trial is active, not recruiting.

Conditions hookworm infection, hookworm disease
Treatments na-gst-1/alhydrogel plus gla-af, na-apr-1 (m74)/alhydrogel, na-apr-1 (m74)/alhydrogel plus gla-af, sterile saline placebo
Phase phase 1
Sponsor Albert B. Sabin Vaccine Institute
Collaborator Centro de Pesquisas René Rachou
Start date September 2015
End date December 2016
Trial size 60 participants
Trial identifier NCT02476773, SVI-DBL-01

Summary

Na-GST-1 and Na-APR-1 are proteins expressed during the adult stage of the Necator americanus hookworm life cycle that are thought to play a role in the parasite's degradation of host hemoglobin for use as an energy source. Vaccination wtih recombinant GST-1 or APR-1 has protected dogs and hamsters from infection in challenge studies. This study will evaluate the safety and immunogenicity of co-administering Na-GST-1 and Na-APR-1 to healthy Brazilian adults living in an area of endemic hookworm infection.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking double blind (subject, investigator, outcomes assessor)
Primary purpose prevention
Arm
(Experimental)
5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel
sterile saline placebo
(Experimental)
5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel plus gla-af
sterile saline placebo
(Experimental)
5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel
sterile saline placebo
(Experimental)
5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel plus gla-af
sterile saline placebo
(Experimental)
5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel
sterile saline placebo
(Experimental)
5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm. 5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm.
na-gst-1/alhydrogel plus gla-af
na-apr-1 (m74)/alhydrogel plus gla-af
sterile saline placebo

Primary Outcomes

Measure
Frequency of solicited injection site and systemic reactogenicity, graded by severity, on the day of each study vaccination through 14 days after each study vaccination.
time frame: 14 days post-vaccination
Frequency of study vaccine-related serious adverse events from the time of the first study vaccination through approximately 9 months after the last study vaccination.
time frame: Day 380
Frequency of clinical safety laboratory adverse events.
time frame: Day 380
Frequency of unsolicited adverse events, graded by severity, from the time of each study vaccination through approximately 1 month after each study vaccination.
time frame: 30 days post-vaccination
Frequency of new-onset chronic medical conditions through approximately 9 months after the third study vaccination.
time frame: Day 380
Frequency of Adverse Events of Special Interest through approximately 9 months after the third study vaccination.
time frame: Day 380

Secondary Outcomes

Measure
The IgG level by an indirect enzyme-linked immunosorbent assay (ELISA) on approximately Day 126.
time frame: Day 126

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: 1. Males or non-pregnant females between 18 and 45 years, inclusive. 2. Good general health as determined by means of the screening procedure. 3. Available for the duration of individual subject study participation (16 months). 4. Willingness to participate in the study as evidenced by signing the informed consent document. Exclusion Criteria: 1. Pregnancy as determined by a positive urine hCG (if female). 2. Subject unwilling to use reliable contraception (as described in Section 2.3.1) from 30 days prior to the first immunization and up until one month following the third immunization (if female and not surgically sterile, abstinent or at least 2 years post-menopausal, or determined otherwise by medical evaluation to be sterile). 3. Currently lactating and breast-feeding (if female). 4. Inability to correctly answer all questions on the informed consent comprehension questionnaire. 5. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies (a history of essential hypertension that is well controlled by medication will not be considered exclusionary.) 6. Has a diagnosis of schizophrenia, bipolar disease or other major psychiatric condition that would make compliance with study visits/procedures difficult (e.g., subject with psychoses or history of suicide attempt or gesture in the 3 years before study entry, ongoing risk for suicide). 7. Known or suspected immunodeficiency. 8. Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25-times the upper reference limit). 9. Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing with the exception of greater than trace blood detected in females during menses). 10. Laboratory evidence of hematologic disease (absolute leukocyte count <3200/mm3; absolute leukocyte count >10.8 x 103/mm3; hemoglobin <11.4 g/dl [females] or <12.1 g/dl [males]; or, platelet count <130,000/mm3). 11. Serum glucose (random) greater than 1.2-times the upper reference limit. 12. Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol. 13. Participation in another investigational vaccine or drug trial within 30 days of starting this study. 14. Previous receipt of the Na-GST-1/Alhydrogel® hookworm vaccine. 15. Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. 16. History of a severe allergic reaction or anaphylaxis. 17. Severe asthma as defined by the need for daily use of inhalers or emergency clinic visit or hospitalization within the last 6 months. 18. Positive test for hepatitis B surface antigen (HBsAg). 19. Positive confirmatory test for HIV infection. 20. Positive confirmatory test for hepatitis C virus (HCV) infection. 21. Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of the volunteer's expected first vaccination in this study or planned use up to one month following the last vaccination. 22. Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to the volunteer's expected first vaccination in the study. 23. History of a surgical splenectomy. 24. Receipt of blood products within the past 6 months. 25. Anti-Na-GST-1 IgE antibody level above 0.35 kUA/L by the ImmunoCAP method. 26. Anti-Na-APR-1 IgE antibody level above ELISA reactivity threshold.

Additional Information

Official title Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel® in Brazilian Adults
Principal investigator David Diemert, MD
Description Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm exposed adults living in the area of Americaninhas, Minas Gerais, Brazil. Subjects will receive three doses of the assigned vaccine delivered intramuscularly on approximately Days 0, 56, and 112. Safety will be measured from the time of each study vaccination (Day 0) through 14 days after each study vaccination by the occurrence of solicited injection site and systemic reactogenicity events. Unsolicited non-serious adverse events (AEs) will be collected from the time of the first study vaccination through approximately 1 month after each study vaccination. New-onset chronic medical conditions and Serious Adverse Events (SAEs) will be collected from the time of the first study vaccination through approximately 9 months after the third study vaccination (final visit). Clinical laboratory evaluations for safety will be performed on venous blood collected approximately 14 days after each vaccination. Immunogenicity testing will include IgG antibody responses to each vaccine antigen, by an indirect enzyme-linked immunosorbent assay (ELISA) and also by ImmunoCAP, on serum obtained prior to each study vaccination and at time points after each vaccination; antibody affinity by Surface Plasmon Resonance; functional activity of vaccine-induced antibodies via in vitro enzyme neutralization assays; and, antigen-specific memory B cell responses. Recruitment and enrollment into the study will occur on an ongoing basis, with each group being recruited and vaccinated in sequence. 60 subjects will be enrolled into 6 groups of 10.
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Albert B. Sabin Vaccine Institute.